Institutions · Entity Annotation Prototype (beta)

1articles mentioning institutions

1institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: KEYNOTE-564 trial ×

KEYNOTE-564 trial

This institution is selected. Its supporting articles are shown below.

KEYNOTE-564 trial1

Articles mentioning KEYNOTE-564 trial

1 articles · page 1 of 1

Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses

jitc · abstract · 2026-07-10 · 1 matching annotations

78.8%

KEYNOTE-564 trial penpulimab Adjuvant penpulimab very-high risk ccRCC adjuvant immunotherapy

…ogeneity in benefit from adjuvant immunotherapy observed in the KEYNOTE-564 trial, together with limited prospective data in this population, war…

Browse institutions

KEYNOTE-564 trial

Articles mentioning KEYNOTE-564 trial

Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses